Rho-associated protein kinase · PROTEIN FAMILY · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Rho-associated protein kinase shows approved-linked disease relevance led by ocular hypertension. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt O75116. Start with ocular hypertension, then reuse UniProt O75116 as the stable protein anchor across project notes and exports.
Start with ocular hypertension, then reuse UniProt O75116 as the stable protein anchor across project notes and exports.
Rho-associated protein kinase shows approved-linked disease relevance led by ocular hypertension. 5 more disease programs remain visible in the same review block. 4 linked drugs remain visible in the same block.
Start review with ocular hypertension because it currently carries approved-linked support. Linked drugs include AMA0076, DE-104, NETARSUDIL DIMESYLATE, VEROSUDIL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyRho-associated protein kinase 2
Review this target as Rho-associated protein kinase, mapped to UniProt O75116. ChEMBL maps the protein component as Rho-associated protein kinase 2. Sequence length is 1388 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Rho-associated protein kinase as ChEMBL target CHEMBL2111459, mapped to UniProt O75116. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Rho-associated protein kinase is the right protein anchor across sources, using UniProt O75116 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why ocular hypertension is currently framed as approved-linked support. It currently carries 4 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Rho-associated protein kinase |
| Target Type | PROTEIN FAMILY |
| Organism | Homo sapiens |
| UniProt | O75116 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Rho-associated protein kinase 2 |
| UniProt Accession | O75116 |
| Component Type | Protein |
| Sequence Length | 1388 aa |
Rho-associated protein kinase 2
Review this target as Rho-associated protein kinase, mapped to UniProt O75116. ChEMBL maps the protein component as Rho-associated protein kinase 2. Sequence length is 1388 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Rho-associated protein kinase shows approved-linked disease relevance led by ocular hypertension. 5 more disease programs remain visible in the same review block.
Start review with ocular hypertension because it currently carries approved-linked support. Linked drugs include AMA0076, DE-104, NETARSUDIL DIMESYLATE, VEROSUDIL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL519123 | 8.82 | IC50 | 1.5 | Preclinical |
| CHEMBL225166 | 8.52 | IC50 | 3.0 | Preclinical |
| CHEMBL224594 | 8.52 | IC50 | 3.0 | Preclinical |
| CHEMBL373512 | 8.3 | IC50 | 5.0 | Preclinical |
| CHEMBL4453941 | 8.22 | Ki | 6.0 | Preclinical |
| CHEMBL388516 | 8.05 | IC50 | 9.0 | Preclinical |
| CHEMBL225582 | 8.0 | IC50 | 10.0 | Preclinical |
| CHEMBL224510 | 8.0 | IC50 | 10.0 | Preclinical |
| CHEMBL224535 | 8.0 | IC50 | 10.0 | Preclinical |
| CHEMBL224166 | 7.96 | IC50 | 11.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 8 | 14 | 6.3 |
| protein format | 6 | 6 | 7.4 |
| protein complex format | 4 | 75 | 7.0 |
| subcellular format | 4 | 0 | — |
| assay format | 1 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 1 | 0 | — |